A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
← catalyst calendarNCT05006716 · readout ≤ 102 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
645estimated
Sites
115
Countries
Australia, Brazil, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-13 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-cell Malignancy
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Non-Hodgkin Lymphoma
- Waldenström Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
Intervention
- Drug: BGB-16673
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Number of Participants with Adverse Events (AEs)
measured From the first dose of BGB-16673 until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)
Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-16673
measured Approximately 28 days
Phase 1: Recommended dose(s) for Expansion (RDFE) of BGB-16673
measured Approximately 3 years
Phase 2: Overall response rate (ORR)
measured approximately 3 years
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed